Inside the deadly disease confounding medicine, researchers piecing together clues and the breakthrough that meant survival ...
Avalyn Pharma's IPO aims to fund inhaled IPF therapies as AP01 shows positive Phase II results. Read the full analysis here.
BOSTON, March 25, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm ...
IOWA CITY — William O’Neal II glances over his laptop screen every time the front door scrapes the sidewalk above, the extended whoooosh of escaping current like an airlock depressurizing. One of ...
After false starts and incremental gains, scientists crack the problem that made breathing impossible. Will answers come fast ...
Haunted by the cystic fibrosis patients he could not help, one Iowa doctor commits his life to understanding what is broken deep inside their cells.
Preclinical data indicate that inhaled treprostinil may be useful for the treatment of idiopathic pulmonary fibrosis (IPF) through an antifibrotic mechanism, a premise that is supported by clinical ...
Idiopathic pulmonary fibrosis, a rare progressive disease characterized by fibrosis in the alveoli of the lungs, has a median survival of 3 to 5 years if left untreated. Inhaled treprostinil slowed ...
CHICAGO, March 5, 2026 /PRNewswire/ -- The Pulmonary Fibrosis Foundation's Care Center Network has grown to include 96 sites in 40 states as part of its first expansion since 2023, marking a milestone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results